As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market rese ...

and South Africa. “We now have a clinical diagnosis for obesity, which has been lacking…The traditional classification based on BMI…reflects simply whether or not there is excess adiposity ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Amgen reported in-line revenues and non-GAAP EPS for the third quarter of 2024, demonstrating stability in its core business. The company's robust financial health is reflected in its EBITDA of $ ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.